{
  "docId": "019de076-b731-71da-a78f-007719e300bb",
  "docSlug": "1616e8b22ac58e7f024f1153201d610f",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 42,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 9,
  "notes": "Uses a 'cite_precedent' framework to validate the strategy by comparing it to the established success of Osimertinib.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b731-71da-a78f-007719e300bb/10",
  "deckHref": "/decks/019de076-b731-71da-a78f-007719e300bb",
  "deckJsonHref": "/decks/019de076-b731-71da-a78f-007719e300bb.json",
  "deckAnchorHref": "/decks/019de076-b731-71da-a78f-007719e300bb#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.32,
        "x": 0.64,
        "y": 0.54
      },
      "kind": "chart",
      "text": "Significant 1L mPFS improvement & Movement up the treatment paradigm",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0530188f-165c-417f-9d80-1610ff1acdf5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.71,
        "x": 0.145,
        "y": 0.215
      },
      "kind": "diagram",
      "text": "Selective inhibition of the oncogenic driver + Overcoming treatment-emergent resistance mutations + Treating & preventing brain metastases + Avoiding treatment-limiting adverse events",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f7954422-3f81-4193-9c5c-c8b52864f8b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.912,
        "x": 0.084,
        "y": 0.463
      },
      "kind": "paragraph",
      "text": "Comparable resistance mutation rates after 1L TKI: ~50% ALK single mutation & ~40% ROS1 G2032R vs. ~50% EGFR T790M",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2903aa26-5608-48f7-ad5a-4a1d39d94cdd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.06,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "Sources: [1] Dagogo-Jack I. et al., Clin Cancer Res 2019; [2] Gainor J. et al. Cancer Discov. 2016; [4] Gainor J.F. et al., JCO Precision Oncol. 2017; [4] Ohashi K. et al., JCO 2013; [5] Osimertinib FDA package insert.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7183c36-2626-43dd-8c6d-7fe1a0a8e169",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.586,
        "x": 0.207,
        "y": 0.155
      },
      "kind": "title",
      "text": "Potential best-in-class ALK & ROS1 TKIs to overcome the combined medical needs of:",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21678480-8f14-48f4-9eb7-c59fb2534ba1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.042,
        "w": 0.504,
        "x": 0.248,
        "y": 0.065
      },
      "kind": "title",
      "text": "Nuvalent ALK+ and ROS1+ NSCLC Strategy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5acf1dce-3606-4dbd-8dc7-f2612c1903bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.34,
        "x": 0.06,
        "y": 0.54
      },
      "kind": "title",
      "text": "CASE STUDY Osimertinib for EGFR+ NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e534cc98-6746-4664-90ac-41566f85b020",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "c9db4b11-7c6f-4723-b94e-593527e477ea",
      "evidence": "chart/bar-horizontal: Significant 1L mPFS improvement & Movement up the treatment paradigm",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "cite_precedent",
      "slug": null,
      "matchId": "dd2b4966-236a-4e15-9fd7-32efd67a970c",
      "evidence": "Uses Osimertinib case study to validate the proposed strategy",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 4,
      "beatId": "1b4ba678-72a5-41ab-80a1-d0e9467146f7",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The deck presents Nuvalent's approach as a potential solution to the problem.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "a5fd2686-9365-4f77-a28b-41b78335203d",
      "evidence": "The deck presents the limitations of current treatment options and the potential benefits of Nuvalent's approach.",
      "position": 0,
      "objective": "Highlight the limitations of current treatment options and the need for new solutions",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}